(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68112 A2

(51) International Patent Classification[7]: A61K 38/00

(21) International Application Number: PCT/EP01/02882

(22) International Filing Date: 14 March 2001 (14.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/189,091 14 March 2000 (14.03.2000) US

(71) Applicants and
(72) Inventors: **GÖKE, Burkhard** [DE/DE]; Römerstrasse 47 a, 82131 Gauting (DE). **SCHIRRA, Jörg** [DE/DE]; Meyerbeerstrasse 4, 81247 München (DE).

(74) Agent: **DÖRRIES, FRANK-MOLNIA & POHLMAN**; Postfach 221661, 80538 Munich (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

G00002

WO 01/68112 A2

(54) Title: EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (7-36) ON ANTRO-PYLORO-DUODENAL MOTILITY

(57) Abstract: The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.